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i n c reased patient knowledge
and motivation for self-care, as
well as improved health-seeking
behaviors that empower indi-
viduals to consult their care
p rovider about problems they
have been hesitant to discuss.
The downside of DTCA is the
i n c reased risk of inappro p r i a t e
or excessive prescriptions, high-
er prescription costs to individu-
als and insurers, as well as the
i n a p p ropriate or over diagnosis
of certain health conditions.
M o re o v e r, many believe DTCA
contributes to consumer misin-
f o rmation, thus putting health
c a re providers in the awkward
and time-consuming position of
convincing patients that the
d rug they are requesting is not in their best intere s t
(Montoya, Lee-Dukes, & Shaw, 2008).
My concern re g a rding DTCA for ED drugs is the
lack of objective evidence that documents the benefits
or limitations of this marketing approach. The deart h
of re s e a rch on this topic, as well as for those dru g s
widely marketed for overactive bladder, re p re s e n t s
t remendous re s e a rch opportunities for urology nurses. 
As for H.R. 2175, I understand the motivation for
the legislation introduced (I still don’t get what a cou-
ple in separate bathtubs on the beach has to do with
sex or ED!), but I wonder whether a legislative
a p p roach is appropriate or needed to address the con-
c e rns re g a rding DTCA for ED drugs. Urologic nurses
have a long history of partnering with the pharm a c e u-
tical industry to provide education to pro f e s s i o n a l s
and patients. Thus, it seems to me that the time has
come for us to engage our pharmaceutical partners in a
serious discussion on how to best provide education
about ED drugs in a way that is responsible, meets the
needs of all stakeholders, and yet, is not offensive to
the public. 
K a ren A. Karlowicz, EdD, MSN, RN
Editorial Board Member
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You’ve seen the commer-cials on television: theguy band singing a well-known Elvis Presley tune
but with diff e rent lyrics; the fifty-
something couple dancing with
wanting looks in their eyes; the
couple in his and her clawfoot
bathtubs on the beach. These are all
images that are part of the dire c t - t o -
consumer advertising (DTCA)
e ff o rt by pharmaceutical compa-
nies that manufacture medications
for erectile dysfunction (ED).
ED is a significant clinical
health problem that urologic care
p rofessionals discuss with ease.
H o w e v e r, many in the general
public find open talk of sexual
health problems an invasion of
p r i v a c y, embarrassing, inappropriate, or even taboo.
The level of discomfort that many have re g a rding this
topic is escalating with the increasing number of com-
m e rcials promoting ED drugs, especially during prime-
time television viewing. In fact, as I write this editori-
al, I have seen no less than four advertisements for ED
d rugs in the hour between 10:00 to 11:00 p.m. on CNN.
F rustrated and outraged by the ads for ED dru g s
on television, on April 29, 2009, Rep. James P. Moran
(VA) introduced H.R. 2175, Families for ED
A d v e rtising Decency Act. This bill is intended to pro-
hibit the broadcasting of any advertisement for med-
ication for the treatment of ED or other purposes. It
has been re f e rred to the House Committee on Energ y
and Commerce for further consideration. 
DTCA has been on the rise world-wide over the
past 15 years, due in part to government eff o rts to
reduce the influence of the pharmaceutical industry on
those with prescriptive authority. With less advert i s i n g
dollars dedicated to activities for health care pro v i d e r s ,
p h a rmaceutical companies have re d i rected their
a d v e rtising budgets for patent-protected, brand name
d rugs to consumer marketing. In 2006, about 40% of
all advertising dollars, totaling an estimated $4.8 bil-
lion, was spent on DTCA by drug companies. In the
years to come, this figure is expected to significantly
i n c rease, with more focus on television advertising to
consumers and less advertising in professional jour-
nals (Polen, Khanfar, & Clauson, 2009). 
Among the re p o rted benefits of DTCA are
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